Europe Heparin Market, By Product Type (Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin), By End User (Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers)), and By Region (North America,

Europe Heparin Market, By Product Type (Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin), By End User (Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa ) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Heparin is obtained naturally from mucosal tissues of slaughtered meat animals such as porcine intestines or bovine lungs or prepared synthetically. It is also known as unfractionated heparin (UFH) and is used as an anticoagulant for treating acute coronary syndrome, atrial fibrillation (AF), venous thromboembolism (VTE), etc. Increasing prevalence of atrial fibrillation in developed and developing economies along with increasing research and development activities is anticipated to drive the market growth during the forecast period. Moreover, major players in the market are also focused on assessing the efficacy of heparin alternatives in the treatment which in turn is also expected to assist the market growth.
Key features of the study:
This report provides in-depth analysis of the Europe Heparin market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Europe Heparin market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., Sanofi S.A., Syntex S.A., LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Europe Heparin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe Heparin market
Detailed Segmentation:
Europe Heparin Market, By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
Europe Heparin Market, By End User:
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
Europe Heparin Market, By Region:
North America
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
U.S.
Canada
Latin America
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
U.K.
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
GCC Countries
Israel
Rest of Middle East
Africa
By Product Type:
Low Molecular Weight Heparin
Unfractionated Heparin
Ultra Low Molecular Weight Heparin
By End User
Hospitals
Blood and Stem Cell Bank
Others (Laboratories, Acute Care Centers)
By Country
North Africa
Central Africa
South Africa
Company Profiles
Pfizer, Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Sagent Pharmaceuticals, Inc.
B. Braun Melsungen AG
Baxter International Inc.
GlaxoSmithKline plc
Bayer AG
Anselm Pharmaceuticals
Bristol-Myers Squibb Co.
Dr. Reddy’s Laboratories Ltd.
Fresenius SE & Co. KGaA
Leap Labchem Co.
LEO Pharma A/S
Sanofi S.A.
Syntex S.A.
Teva Pharmaceutical Industries Ltd.
United Biotech (P) Ltd
Amphastar Pharmaceuticals Inc.
Abbott Laboratories
Aspen Pharmacare Holdings
Laboratorios Farmaceuticos ROVI SA
Intrapharm Laboratories
“*” marked represents similar segmentation in other categories in the respective section.